Patrick Cushing Email & Phone Number

Groton, MA, US

Laupheim, Baden-Württemberg, DE

Responsible for operations at the Milford site encompassing Process Science, MSAT, Engineering, Validation, Metrology, Facilities, Supply Chain, and both clinical and commercial Manufacturing.

Laupheim, Baden-Württemberg, DE

Laupheim, Baden-Württemberg, DE

-Managed the Milford site (250 employees) on an interim basis with 3 colleagues as an Executive Leadership Team (ELT) April 2023 - September 2023-Member of Milford site Senior Leadership Team (SLT) and COVID-19 Safety Committee-Responsible for Milford site process development, process tech transfer, and analytical method establishment -Led upstream &.

-Direct process development activities to support GMP manufacturing-Support GMP facility start-up -Author GMP batch records, in-process, release, and material specifications-Purify protein and pDNA targets via affinity, IEX, HIC, and SEC methods ranging from low-microgram to mid-gram scale (< 100 g). -Characterize biologics via SDS-PAGE, western blot, UV.

-Purified protein via affinity, IEX, HIC, and SEC chromatography (see below).-Established pricing metrics for protein purification and characterization service offerings. -Characterized purified proteins via SDS-PAGE, Western blot, analytical SEC, and DSF.-Additional responsibilities included project management (project scheduling, communicating updates.

-Developed, optimized, and implemented purification strategies for both cytosolic and secreted proteins utilizing tangential flow filtration (TFF), affinity chromatography (protein A, IMAC, Flag, Strep, Heparin, GST), ion exchange chromatography, hydrophobic interaction chromatography, and size-exclusion chromatography.

-Developed and optimized purification strategies for 6 kinases in milligram scale quantities for small-molecule screening, protein crystallization and biophysical assays. -Screened and optimized conditions for protein-inhibitor co-crystallization. Co-crystallized 22 complexes; solved and refined 3 high-resolution inhibitor-bound co-crystal.

Hanover, NH, US

-Purified numerous PDZ proteins (wild-type and binding site mutants) including gram quantities of the CAL PDZ domain for use in high-throughput inhibitor screens-Consulted on-site with The Broad Institute to adapt a fluorescence anisotropy binding assay to high-throughput format, facilitating a 326,000 compound screen for PDZ inhibitors. Implemented a.

-Optimized protein constructs and purified PDZ proteins for binding studies including isotope labeled protein for NMR HSQC spectroscopy.-Designed, developed, and optimized numerous in vitro protein binding assays ranging from low-throughput (pull-down) to high-throughput (fluorescence anisotropy, Förster Resonance Energy Transfer (FRET), AlphaScreen, NMR.

-Developed and optimized purification strategies for wild-type and site-directed mutant forms of protein targets. -Optimized assay conditions for an ELISA assay that was adapted for high-throughput inhibitor screens.

Ph.D., Biochemistry

B.S., Chemistry